|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Preclinical Experimental Therapeutics |
Northwestern University Institute for Neuroscience (M.V., E.W.-Y.K., Y.N., A.E., D.R.G.) and Department of Neurobiology and Physiology (M.V., E.W.-Y.K., D.R.G.), Northwestern University, Evanston, IL 60208; and Department of Neurology, Northwestern University Medical School, Evanston Northwestern Healthcare, Evanston, IL 60201 (M.J.A., C.V.A., D.R.G.); USA
2 Send correspondence to Dennis R. Groothuis, Department of Neurology, Evanston Northwestern Healthcare, 2650 Ridge Avenue, Evanston, IL 60201, USA (drgroothuis{at}northwestern.edu).
Abstract
We compared tissue and plasma pharmacokinetics of 14C-sucrose in subcutaneous RG-2 rat gliomas after administration by 3 routes, intravenous bolus (IV-B; 50 µCi over 30 s), continuous IV infusion (IV-C, 50 µCi at a constant rate), and convection-enhanced delivery (CED, 5 µCi infused at a rate of 0.5 µl/min), and for 3 experimental durations, 0.5, 2, and 4 h. Plasma, tumor, and other tissue samples were obtained to measure tissue radioactivity. Plasma radioactivity in the CED group increased exponentially and lagged only slightly behind the IV-C group. After 90 min, plasma values were similar in all. Mean tumor radioactivity was 100 to 500 times higher in the CED group at each time point than in the IV-B and IV-C groups. Tumor radioactivity was homogeneous in the IV groups at 0.5 h and inhomogeneous at 1 and 2 h. In CED, radioactivity distribution was inhomogeneous at all 3 time points; highest concentrations were in tissue around tumor and in necrosis, while viable tumor contained the lowest and sometimes negligible amounts of isotope. Systemic tissue radioactivity values were similar in all groups. Efflux of 14C-sucrose from tumors was evaluated in intracerebral tumors (at 0.5, 1, 2, and 4 h) and subcutaneous tumors (at 0 to 0.5 h). Less than 5% of 14C activity remained in intracerebral tumors at each time point. The efflux half-time from the subcutaneous tumors was 7.3 ± 0.7 min. These results indicate rapid efflux of drug from brain tumor and marked heterogeneity of drug distribution within tumor after CED administration, both of which may be potentially limiting factors in drug delivery by this method.
References
Baxter, L.T., and Jain, R.K. (1989) Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res. 37,77 -104.[CrossRef][Web of Science][Medline]
Blasberg, R.G., Groothuis, D.R., and Molnar, P. (1981) Application of quantitative autoradiographic measurements in experimental brain tumors. Semin. Neurol. 1, 203-224.
Bobo, R.H., Laske, D.W., Akbasak, A., Morrison, P.F., Dedrick,
R.L., and Oldfield, E.H. (1994) Convection enhanced delivery of
macromolecules in the brain. Proc. Natl. Acad. Sci.
USA 91,2076
-2080.
Boucher, Y., and Jain, R.K. (1992) Microvascular
pressure is the principal driving force for interstitial hypertension in solid
tumors: Implications for vascular collapse. Cancer
Res. 52,5110
-5114.
Boucher, Y., Baxter, L.T., and Jain, R.K. (1990)
Interstitial pressure gradients in tissue-isolated and subcutaneous tumors:
Implications for therapy. Cancer Res.
50,4478
-4484.
Boucher, Y., Salehi, H., Witwer, B., Harsh, G.R. 4th, and Jain, R.K. (1997) Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br. J. Cancer 75,829 -836.[Web of Science][Medline]
Bruce, J.N., Falavigna, A., Johnson, J.P., Hall, J.S., Birch, B.D., Yoon, J.T., Wu, E.X., Fine, R.L., and Parsa, A.T. (2000) Intracerebral clysis in a rat glioma model. Neurosurgery 46,683 -691.[CrossRef][Web of Science][Medline]
Cserr, H.F., Cooper, D.N., Suri, P.K., and Patlak, C.S. (1981) Efflux of radio-labeled polyethylene glycols and albumin from rat brain. Am. J. Physiol. 240,F319 -F328.
Giussani, C., Carrabba, G., Pluderi, M., Lucini, V., Pannacci, M.,
Caronzolo, D., Costa, F., Minotti, M., Tomei, G., Villani, R., Bikfalvi, A.,
and Bello, L. (2003) Local intracerebral delivery of endogenous
inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo.
Cancer Res. 63,2499
-2505.
Groothuis, D.R., Fischer, J.M., Pasternak, J.F., Blasberg, R.G.,
Bigner, D.D., and Vick, N.A. (1983a) Regional measurements of
blood-to-tissue transport in transplanted RG-2 rat gliomas. Cancer
Res. 43,3368
-3373.
Groothuis, D.R., Pasternak, J.F., Fischer, J.M., Blasberg, R.G.,
Vick, N.A., and Bigner, D.D. (1983b) Regional measurements of
blood flow in transplanted RG-2 rat gliomas. Cancer
Res. 43,3362
-3367.
Groothuis, D.R., Ward, S., Itskovich, A.C., Dobrescu, C., Allen, C.V., Dills, C., and Levy, R.M. (1999) Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J. Neurosurg. 90,321 -331.[Web of Science][Medline]
Hassenbusch, S., Levin, V., Cozzens, J., Paleologos, N., Smith, D., Phuphanich, S., Brem, S., Chen, T., Chamberlain, M., Hariharan, S., Krouwer, H., Mueller, W., Resnick, G., and Pietronigro, D. (2002) Multi-center phase I/II trial of stereotactic injection of DTI-015 into inoperable recurrent malignant glioblastoma multiforme. Neuro-oncol. 4,S43 (abstract).
Heimberger, A.B., Archer, G.E., McLendon, R.E., Hulette, C.,
Friedman, A.H., Friedman, H.S., Bigner, D.D., and Sampson, J.H.
(2000) Temozolomide delivered by intracerebral microinfusion is
safe and efficacious against malignant gliomas in rats. Clin.
Cancer Res. 6,4148
-4153.
Jain, R.K. (1990) Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 9,253 -266.[CrossRef][Web of Science][Medline]
Kaiser, M.G., Parsa, A.T., Fine, R.L., Hall, J.S., Chakrabarti, I., and Bruce, J.N. (2000) Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 47,1391 -1398.[Web of Science][Medline]
Kristjansen, P.E., Boucher, Y., and Jain, R.K. (1993)
Dexamethasone reduces the interstitial fluid pressure in a human colon
adenocarcinoma xenograft. Cancer Res.
53,4764
-4766.
Laske, D.W., Ilercil, O., Akbasak, A., Youle, R.J., and Oldfield, E.H. (1994) Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg. 80,520 -526.[Web of Science][Medline]
Laske, D.W., and Rossi, P. (2002) Phase II multicenter trial of intratumoral/interstitial therapy with TransMID in patients with refractory and progressive glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) Neuro-oncol. 4, S58 (abstract).
Less, J.R., Posner, M.C., Boucher, Y., Borochovitz, D., Wolmark,
N., and Jain, R.K. (1992) Interstitial hypertension in human
breast and colorectal tumors. Cancer Res.
52,6371
-6374.
Mardor, Y., Roth, Y., Lidar, Z., Jonas, T., Pfeffer, R., Maier,
S.E., Faibel, M., Nass, D., Hadani, M., Orenstein, A., Cohen, J.S., and Ram,
Z. (2001) Monitoring response to convection-enhanced taxol
delivery in brain tumor patients using diffusion-weighted magnetic resonance
imaging. Cancer Res. 61,4971
-4973.
Miller, C.R., Williams, C.R., Buchsbaum, D.J., and Gillespie, G.Y.
(2002) Intratumoral 5-fluorouracil produced by cytosine
deaminase/5-fluorocytosine gene therapy is effective for experimental human
glioblastomas. Cancer Res.
62,773
-780.
Molnar, P., Fekete, I., Schlageter, K.E., Lapin, G.D., and
Groothuis, D.R. (1999) Absence of host-site influence on
angiogenesis, blood flow, and permeability in transplanted RG-2 gliomas.
Drug Metab. Dispos. 27,1085
-1091.
Netti, P.A., Baxter, L.T., Boucher, Y., Skalak, R., and Jain, R.K.
(1995) Time dependent behavior of interstitial fluid pressure in
solid tumors: Implications for drug delivery. Cancer
Res. 55,5451
-5458.
Patchell, R.A., Regine, W.F., Ashton, P., Tibbs, P.A., Wilson, D., Shappley, D., and Young, B. (2002) A phase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 60, 37-42.[Medline]
Paxinos, G., and Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd ed. Orlando: Academic Press.
Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., Quinn, J., Rich, J., Penne, K., Sampson, J., Shafman, T., Wong, T., Zalutsky, M., and Bigner, D. (2002) Treatment of patients with newly diagnosed malignant gliomas using iodine 131-labeled human-mouse chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities: Phase I/II trial results. Neuro-oncol. 4,S80 (abstract).
Schlageter, K.E., Molnar, P., Lapin, G.D., and Groothuis, D.R. (1999) Microvessel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvasc. Res. 58,312 -328.[CrossRef][Web of Science][Medline]
Viola, J.J., Agbaria, R., Walbridge, S., Oshiro, E.M., Johns, D.G.,
Kelley, J.A., Oldfield, E.H., and Ram, Z. (1995) In situ
cyclopentenyl cytosine infusion for the treatment of experimental brain
tumors. Cancer Res. 55,1306
-1309.
Weber, F.W., and Hingorani, V. (2002) Local treatment of recurrent glioblastoma by bulk infusion of recombinant IL-4 immunotoxin. Neuro-oncol. 4,S101 (abstract).
Yang, W., Barth, R.F., Adams, D.M., Ciesielski, M.J., Fenstermaker,
R.A., Shukla, S., Tjarks, W., and Caligiuri, M.A. (2002)
Convection-enhanced delivery of boronated epidermal growth factor for
molecular targeting of EGF receptor-positive gliomas. Cancer
Res. 62,6552
-6558.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Navalitloha, E. S. Schwartz, E. N. Groothuis, C. V. Allen, R. M. Levy, and D. R. Groothuis Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors Neuro-oncol, July 1, 2006; 8(3): 227 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ali, Y. Navalitloha, M. W. Vavra, E. W.-Y. Kang, A. C. Itskovich, P. Molnar, R. M. Levy, and D. R. Groothuis Isolation of drug delivery from drug effect: Problems of optimizing drug delivery parameters Neuro-oncol, April 1, 2006; 8(2): 109 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Carpentier, F. Laigle-Donadey, S. Zohar, L. Capelle, A. Behin, A. Tibi, N. Martin-Duverneuil, M. Sanson, L. Lacomblez, S. Taillibert, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma Neuro-oncol, January 1, 2006; 8(1): 60 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Barth, W. Yang, A. S. Al-Madhoun, J. Johnsamuel, Y. Byun, S. Chandra, D. R. Smith, W. Tjarks, and S. Eriksson Boron-Containing Nucleosides as Potential Delivery Agents for Neutron Capture Therapy of Brain Tumors Cancer Res., September 1, 2004; 64(17): 6287 - 6295. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
